• Science & Technology
    • Technology Overview
  • Medical Applications
    • COVID-19
    • Respiratory Infections
  • Security Applications
    • Security Applications
  • About
    • About Ancon
    • Management Team
    • Papers and Articles
    • News and Events
    • Investors
© All rights reserved.
Ancon Technologies Ancon Technologies
  • Science & Technology
    • Technology Overview
  • Medical Applications
    • COVID-19
    • Respiratory Infections
  • Security Applications
    • Security Applications
  • About
    • About Ancon
    • Management Team
    • Papers and Articles
    • News and Events
    • Investors
Contact Us
Ancon Technologies

About Ancon

Our Mission

To save lives and make a difference to society from the early, accurate and actionable detection of trace volatile organic compounds from a single, affordable test.

Futuristic laboratory equipment. Team studying medical samples using microscope

Potentially market leading position in the breath-based COVID-19 diagnostics sector

Ancon is a UK-based company that has developed proprietary technologies for the detection of trace quantities of Volatile Organic Compounds (VOCs).These technologies have a number of important medical applications including breath-based diagnostic testing for cancers, bacteria and viruses, including COVID-19. They also offer significantly improved detection of explosives, narcotics and chemical threats.

Ancon’s technology has the potential to provide faster diagnosis, point of care non-invasive detection, higher sensitivity and a more affordable alternative to current methods in detecting VOCs.

Led by a highly experienced management and scientific team, Ancon is operating in a market that is  large and continuing to grow, with opportunities for partners that are scalable and attractive.

Please contact us with any enquiries.

Contact Us

Ancon’s AI/ML technology has the potential to become a powerful tool in medical care and a fundamental part of digital healthcare with applications across multiple disease areas including perioperative infections, MRSA/MSSA, lung cancer and neurodegenerative disease.

With several ongoing clinical studies, Ancon is a potential market leader in the breath-based COVID-19 diagnostics sector.

3d virus illustration
Proprietary AI/ML Technology

Why Ancon's Technology Is So Exciting:

Point of need – rapid results on site within 10 minutes

Non-invasive – no injections, anaesthetic or bodily intrusions

Increased accuracy vs reference testing due to powerful ML – powerful proprietary ML means significantly better specificity and sensitivity due to pattern recognition

More specific than currently employed PCR tests – MLBA detects active/infectious viruses and bacteria. PCR detects both active and harmless DNA and RNA fragments

Easy to use – minimal training required

Low cost – enable mass screening for many diseases

Mobile – machine is light weight and portable

Personalised – trending and sequential tests available on an individual by individual basis

AI & ML technology – enables continuous improvements in profiling

Early stage detection of disease

Company

About Us
Contact Us

Information

Privacy Policy and Website Terms of Use

Subscribe to Newsletter
(by clicking subscribe, you agree to our privacy policy)

Ancon logo white

All images used are for reference purposes only.

© 2021 Ancon Technologies
Theme by genapse

in
F.A.Q
Support Forum
Video Tutorials

Search panel can contain any widgets and shortcodes.

Call us: 0 800 255 22 55
We may use cookies to ensure that we give you the best experience on our website. If you continue to use this site we will assume that you are happy with this. Please review our website privacy policy and terms of use for more information. AcceptPrivacy policy